Showing 1 posts of 1 posts found.
The US Food and Drug Administration (FDA) has announced that it has approved RiVive, 3mg naloxone hydrochloride nasal spray for …
EHP Awards 2027 open for entries following outstanding inaugural year
NHS spends £240m storing patient records as digital reforms gather pace
NHS awards national diabetes education contract to Leicester programme
InnoScot highlights NHS Scotland’s progress towards net zero healthcare
NHS England approves delayed-release treatment for rare kidney disease